Heron's non-opioid HTX-011 gets Priority Review

Heron's non-opioid HTX-011 gets Priority Review

Source: 
BioCentury
snippet: 

FDA accepted and granted Priority Review to an NDA for HTX-011 from Heron Therapeutics Inc. (NASDAQ:HRTX) for postoperative pain management. The PDUFA date is April 30.